These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

472 related items for PubMed ID: 15823761

  • 1. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis.
    Furst DE.
    Clin Ther; 2004 Dec; 26(12):1960-75. PubMed ID: 15823761
    [Abstract] [Full Text] [Related]

  • 2. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
    Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, Hanrahan PS, Kraishi MM, Patel A, Sun G, Bear MB, 990145 Study Group.
    Ann Rheum Dis; 2004 Sep; 63(9):1062-8. PubMed ID: 15082469
    [Abstract] [Full Text] [Related]

  • 3. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ, McCabe D.
    Arthritis Rheum; 2002 Mar; 46(3):614-24. PubMed ID: 11920396
    [Abstract] [Full Text] [Related]

  • 4. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.
    Tesser J, Fleischmann R, Dore R, Bennett R, Solinger A, Joh T, Modafferi D, Schechtman J, 990757 Study Group.
    J Rheumatol; 2004 Apr; 31(4):649-54. PubMed ID: 15088288
    [Abstract] [Full Text] [Related]

  • 5. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.
    Nuki G, Bresnihan B, Bear MB, McCabe D, European Group Of Clinical Investigators.
    Arthritis Rheum; 2002 Nov; 46(11):2838-46. PubMed ID: 12428223
    [Abstract] [Full Text] [Related]

  • 6. [Interleukin-1 receptor antagonists in the treatment rheumatoid arthritis].
    Zoń-Giebel A, Kotulska A, Giebel S, Cader SA, Kucharz EJ.
    Przegl Lek; 2002 Nov; 59(11):916-8. PubMed ID: 12715722
    [Abstract] [Full Text] [Related]

  • 7. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial.
    Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, Modafferi D, Poulakos J, Sun G.
    Arthritis Rheum; 2003 Apr; 48(4):927-34. PubMed ID: 12687534
    [Abstract] [Full Text] [Related]

  • 8. [Interleukin-1 receptor antagonist anakinra (Kineret) for treatment of rheumatic arthritis].
    Rubbert-Roth A, Perniok A.
    Z Rheumatol; 2003 Aug; 62(4):367-77. PubMed ID: 12928941
    [Abstract] [Full Text] [Related]

  • 9. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.
    Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, Bekker P, 20000223 Study Group.
    Arthritis Rheum; 2004 May; 50(5):1412-9. PubMed ID: 15146410
    [Abstract] [Full Text] [Related]

  • 10. Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy.
    Cohen SB, Strand V, Aguilar D, Ofman JJ.
    Rheumatology (Oxford); 2004 Jun; 43(6):704-11. PubMed ID: 14997006
    [Abstract] [Full Text] [Related]

  • 11. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores.
    Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, McCabe D.
    Arthritis Rheum; 2000 May; 43(5):1001-9. PubMed ID: 10817552
    [Abstract] [Full Text] [Related]

  • 12. Addressing the safety of anakinra in patients with rheumatoid arthritis.
    Fleischmann RM.
    Rheumatology (Oxford); 2003 May; 42 Suppl 2():ii29-35. PubMed ID: 12817093
    [Abstract] [Full Text] [Related]

  • 13. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial.
    Le Loët X, Nordström D, Rodriguez M, Rubbert A, Sarzi-Puttini P, Wouters JM, Woolley JM, Wright N, Lawrence C, Appleton B.
    J Rheumatol; 2008 Aug; 35(8):1538-44. PubMed ID: 18634163
    [Abstract] [Full Text] [Related]

  • 14. Anakinra: new preparation. Weakly effective in rheumatoid arthritis.
    Prescrire Int; 2004 Apr; 13(70):43-5. PubMed ID: 15148945
    [Abstract] [Full Text] [Related]

  • 15. Bringing the clinical experience with anakinra to the patient.
    Cohen SB, Rubbert A.
    Rheumatology (Oxford); 2003 May; 42 Suppl 2():ii36-40. PubMed ID: 12817094
    [Abstract] [Full Text] [Related]

  • 16. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
    Cohen SB.
    Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
    [Abstract] [Full Text] [Related]

  • 17. [Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist].
    Suzuki T.
    Nihon Rinsho; 2002 Dec; 60(12):2397-400. PubMed ID: 12510368
    [Abstract] [Full Text] [Related]

  • 18. Preventing joint damage as the best measure of biologic drug therapy.
    Bresnihan B.
    J Rheumatol Suppl; 2002 Sep; 65():39-43. PubMed ID: 12236622
    [Abstract] [Full Text] [Related]

  • 19. Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study.
    Karanikolas G, Charalambopoulos D, Vaiopoulos G, Andrianakos A, Rapti A, Karras D, Kaskani E, Sfikakis PP.
    Rheumatology (Oxford); 2008 Sep; 47(9):1384-8. PubMed ID: 18603660
    [Abstract] [Full Text] [Related]

  • 20. Safety of extended treatment with anakinra in patients with rheumatoid arthritis.
    Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R, Modafferi D, Zhou L, Bell D, Appleton B.
    Ann Rheum Dis; 2006 Aug; 65(8):1006-12. PubMed ID: 16396977
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.